Restenosis After Angioplasty

Restenosis after angioplasty remains a key challenge in percutaneous coronary interventions, where treated arteries narrow again despite initial success. Primarily seen in coronary artery disease management, it arises from an exaggerated healing response. The procedure—balloon inflation or stenting—injures the vessel wall, triggering smooth muscle cell proliferation and extracellular matrix deposition, forming neointimal hyperplasia. This scar tissue buildup typically manifests 3-6 months post-procedure, with in-stent restenosis (ISR) affecting about 25% of cases using bare-metal stents.

Risk factors include diabetes, small vessel diameter, long lesions, and procedural issues like under-expansion or stent malapposition. Without stents, restenosis rates climb to 40%, underscoring stent utility. Symptoms mirror original atherosclerosis: angina, dyspnea, fatigue, or arrhythmias, prompting urgent evaluation via angiography.

Management evolves with drug-eluting stents (DES) and drug-coated balloons (DCB), releasing antiproliferative agents like paclitaxel to curb cell growth, slashing ISR to under 10%. Repeat angioplasty, brachytherapy, or bypass surgery addresses failures. Preventive dual antiplatelet therapy and optimized implantation enhance outcomes. Ongoing trials explore bioresorbable scaffolds and gene therapy for durable patency.

This diagram illustrates restenosis progression, from balloon angioplasty to stent deployment, highlighting bare-metal versus drug-eluting options in preventing recurrence.